Abstract

HIV neutralizing antibodies (nAbs) represent an important tool in view of prophylactic and therapeutic applications for HIV-1 infection. Patients chronically infected by HIV-1 represent a valuable source for nAbs. HIV controllers, including long-term non-progressors (LTNP) and elite controllers (EC), represent an interesting subgroup in this regard, as here nAbs can develop over time in a rather healthy immune system and in the absence of any therapeutic selection pressure. In this study, we characterized two particular antibodies that were selected as scFv antibody fragments from a phage immune library generated from an LTNP with HIV neutralizing antibodies in his plasma. The phage library was screened on recombinant soluble gp140 envelope (Env) proteins. Sequencing the selected peptide inserts revealed two major classes of antibody sequences. Binding analysis of the corresponding scFv-Fc derivatives to various trimeric and monomeric Env constructs as well as to peptide arrays showed that one class, represented by monoclonal antibody (mAb) A2, specifically recognizes an epitope localized in the pocket binding domain of the C heptad repeat (CHR) in the ectodomain of gp41, but only in the trimeric context. Thus, this antibody represents an interesting tool for trimer identification. MAb A7, representing the second class, binds to structural elements of the third variable loop V3 and neutralizes tier 1 and tier 2 HIV-1 isolates of different subtypes with matching critical amino acids in the linear epitope sequence. In conclusion, HIV controllers are a valuable source for the selection of functionally interesting antibodies that can be selected on soluble gp140 proteins with properties from the native envelope spike.

Highlights

  • NAbs against HIV-1 have been associated with protective immunity in numerous animal studies including the simian/ human immunodeficiency virus (SHIV) macaque model [1,2,3,4,5,6,7,8,9] and transgenic humanized mice [10,11,12,13,14]

  • Neutralizing antibodies are clearly associated with protection from HIV-1 infection [65], recent publications suggest a potential beneficial role of these antibodies in chronic infection

  • The therapeutic efficacy of neutralizing antibodies during chronic infection was very recently verified in two SHIV/ macaque studies [15,16]

Read more

Summary

Introduction

NAbs against HIV-1 have been associated with protective immunity in numerous animal studies including the simian/ human immunodeficiency virus (SHIV) macaque model [1,2,3,4,5,6,7,8,9] and transgenic humanized mice [10,11,12,13,14]. The original set of four well characterized bnmAbs (b12 [18], 2F5 [19], 4E10 [20] and 2G12 [21,22]) has been rapidly expanded during the last few years by direct cloning from Env-specific B-cells from chronically infected patients with bnAbs in plasma [23,24,25,26,27,28,29]. These much more potent mAbs essentially target four regions in the native trimeric. We previously identified LTNP and EC with neutralizing activity in plasma and dissected the humoral immune response

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call